(ANSA) - WASHINGTON, MAY 19 - The US is accelerating to emancipate itself from the dependence of pharmaceutical products on China and India. The Trump administration has signed a $ 354 million four-year contract with Phlow, a Virginia-based pharmaceutical company, for the production of pharmaceuticals are tested or used in the fight against Covid-19 and other drugs that are lacking in the US and which are generally imported from abroad, especially from China and India. The contract, with options for an additional $ 458 million, allows Phlow to replenish national strategic stocks with more than 1.6 million doses of five generic drugs used to treat coronavirus.
"For too long, we have relied on foreign production and distribution chains for our most important medicines and active ingredients, putting national health and safety at serious risk," explained Peter Navarro, White House manager for commercial and productive policies.
345 million contract for drugs in the USA
2020-05-19T14:16:59.182Z
The US is accelerating to emancipate itself from the dependence of pharmaceutical products on China and India. (HANDLE)